Hemolytic uremic syndrome study in children
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This study looks at how common hemolytic uremic syndrome (HUS) is in children. HUS is a rare condition that affects blood cells and kidneys, and this research will help doctors understand it better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be under 18 years old.
- You must have been diagnosed with HUS, which includes having broken red blood cells, low platelet counts, and sudden kidney problems.
- Your medical records must be complete and show the diagnosis clearly.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how rare gene mutations may explain atypical HUS (aHUS) and how that could guide more personalized treatment. It mainly involves people who have had aHUS affecting blood counts and kidneys.
This is a registry that collects information from people diagnosed with atypical hemolytic uremic syndrome (aHUS). It helps researchers better understand the condition across different genetic causes and treatment needs.
This study tests a new medicine called INM004 in children with STEC-HUS, a serious illness that damages the kidneys and blood cells. It may help speed up recovery and prevent complications.
This study looks at children who have visible blood in their urine to find the cause and understand patterns. It is for children from 1 month to 16 years old and involves tests and follow-up for 3 months.
This trial tests a way to use hydroxyurea more safely and effectively in children with sickle cell anemia. It may help doctors fine-tune dosing to reduce complications and side effects.
This study follows children with a horseshoe kidney to understand how the condition affects kidney health and to identify any related birth defects. It may help researchers learn more about this condition and improve care.
Hear when a new Prevalence of Hemolytic Uremic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.